The global dialysis induced anemia treatment market size is expected to be valued at US$ 1.9 billion in 2026 and projected to reach US$ 3.0 billion, growing at a CAGR of 6.8% between 2026 and 2033. The dialysis-induced anemia treatment includes therapies to manage anemia in patients with chronic kidney disease (CKD) undergoing dialysis, where reduced erythropoietin production, iron deficiency, and blood loss contribute to low hemoglobin levels.

The market includes erythropoiesis-stimulating agents (ESAs), iron therapies, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, blood transfusions, and supportive treatments. The market growth is driven by the rising prevalence of CKD and end-stage kidney disease (ESKD), increasing dialysis patient populations, growing adoption of innovative oral HIF-PH inhibitors, and supportive reimbursement policies in developed markets. Ongoing clinical advancements and improved patient management strategies are further expanding treatment options and driving market growth.

Drivers - Rising Global Prevalence of Chronic Kidney Disease and Dialysis Populations

The increasing global burden of chronic kidney disease (CKD) and the growing number of patients progressing to end-stage kidney disease (ESKD) requiring long-term dialysis remain the primary drivers of the Dialysis-Induced Anemia Treatment Market. According to the United States Renal Data System (USRDS) and the International Society of Nephrology (ISN), the number of individuals undergoing hemodialysis and peritoneal dialysis continues to increase due to the rising prevalence of diabetes, hypertension, obesity, and aging population.

As damaged kidneys produce insufficient erythropoietin, anemia develops in the majority of dialysis patients, necessitating long-term treatment with erythropoiesis-stimulating agents (ESAs), iron supplementation, HIF-PH inhibitors, and supportive therapies. Governments across developed and emerging economies are also investing in expanding dialysis infrastructure and improving access to renal replacement therapy, further increasing the number of patients eligible for anemia management. Pharmaceutical companies such as Amgen Inc., Astellas Pharma Inc., CSL Vifor, and Akebia Therapeutics continue to strengthen their renal care portfolios through product innovation and strategic collaborations. As CKD prevalence continues to rise worldwide, the expanding dialysis population will remain a strong and sustainable source of demand for dialysis-induced anemia therapies throughout the forecast period.

Growing Adoption of Novel Oral HIF-PH Inhibitor Therapies

The rapid emergence and clinical adoption of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are significantly transforming the treatment landscape for dialysis-induced anemia. Unlike conventional injectable erythropoiesis-stimulating agents (ESAs), HIF-PH inhibitors stimulate endogenous erythropoietin production through the body's natural oxygen-sensing pathway while also improving iron metabolism, offering a more physiological approach to anemia management. Their oral administration enhances patient convenience, reduces dependence on healthcare facilities for injections, and improves treatment adherence, particularly among patients receiving home dialysis. Growing clinical evidence demonstrating comparable efficacy, favorable cardiovascular safety profiles, and improved hemoglobin control has strengthened physician confidence in this therapeutic class.

Regulatory approvals of products such as Vafseo® (vadadustat), Jesduvroq® (daprodustat), and Evrenzo® (roxadustat) across multiple regions have accelerated commercialization and expanded treatment options for healthcare providers. Pharmaceutical companies including Akebia Therapeutics, GSK plc, FibroGen, Inc., and Astellas Pharma Inc. continue to invest in clinical trials, lifecycle management, and geographic expansion to increase market penetration. As healthcare systems increasingly prioritize convenient, patient-centric therapies and oral treatment options, HIF-PH inhibitors are expected to become a major growth engine for the Dialysis-Induced Anemia Treatment Market over the coming years.

Restraints- Safety Concerns Associated with Erythropoiesis-Stimulating Agents

Long-term use of erythropoiesis-stimulating agents has raised clinical concerns regarding cardiovascular risks, including elevated risk of stroke and thromboembolic events at higher hemoglobin target levels. Regulatory guidance from agencies such as the FDA has introduced boxed warnings and conservative dosing recommendations for ESA therapies, prompting physicians to adopt more cautious prescribing practices. These safety considerations can limit treatment intensity and require careful patient monitoring, potentially constraining broader utilization of ESA-based anemia management protocols across dialysis centers.

High Treatment Costs and Reimbursement Limitations

Dialysis induced anemia treatments, particularly novel HIF-PH inhibitors and advanced iron therapy formulations, often carry substantial treatment costs that can strain healthcare budgets and patient affordability. Reimbursement policies vary significantly across regions and insurance providers, creating access disparities for patients requiring long-term anemia management. This cost burden can be particularly challenging in emerging markets and among underinsured populations, potentially limiting broader adoption of newer, more expensive treatment options despite their clinical advantages over conventional therapies.

Opportunities - Expanding Access to HIF-PH Inhibitor Therapies in Emerging Markets

The expanding regulatory approvals and commercialization of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors across emerging economies represent a significant growth opportunity for the Dialysis-Induced Anemia Treatment Market. Unlike conventional erythropoiesis-stimulating agents (ESAs), which require injectable administration and cold-chain logistics, HIF-PH inhibitors are orally administered, improving patient convenience and reducing healthcare resource use. These therapies are particularly valuable in countries where dialysis infrastructure and healthcare workforce availability remain limited. Pharmaceutical companies such as Kyowa Kirin Co., Ltd., Akebia Therapeutics, GSK plc, and FibroGen, Inc. are actively pursuing regulatory approvals, geographic expansion, and strategic partnerships to strengthen their presence across Asia Pacific, Latin America, and the Middle East. Furthermore, increasing government investments in chronic kidney disease (CKD) management, expanding dialysis center networks, and improving healthcare reimbursement are expected to accelerate the adoption of innovative oral anemia therapies. As the dialysis patient population continues to rise in emerging markets, manufacturers offering cost-effective, accessible, and clinically differentiated HIF-PH inhibitors are well positioned to capture substantial untapped market potential.

Growing Adoption of Home-Based Dialysis and Anemia Management

The increasing adoption of home-based dialysis, including peritoneal dialysis and home hemodialysis, is creating new opportunities for providers of dialysis-induced anemia therapies. Healthcare systems worldwide are encouraging home dialysis to reduce hospital burden, improve patient quality of life, and lower overall treatment costs. This transition is driving demand for anemia therapies that can be conveniently administered outside clinical settings, particularly oral HIF-PH inhibitors and long-acting subcutaneous erythropoiesis-stimulating agents (ESAs).

Companies such as CSL Vifor, Vifor Pharma, Akebia Therapeutics, and GSK plc are expanding treatment portfolios designed to support decentralized patient care through simplified dosing schedules and improved treatment adherence. Additionally, advancements in remote patient monitoring, telehealth services, and digital disease management platforms are enabling healthcare providers to monitor hemoglobin levels and adjust therapy without frequent hospital visits. As governments and healthcare providers continue promoting patient-centered care and home-based renal replacement therapies, manufacturers offering flexible, easy-to-administer anemia treatments are expected to gain a strong competitive advantage and unlock sustained long-term market growth.

Treatment Type Insights

Erythropoiesis-stimulating agents (ESAs) is the leading treatment type segment, commanding approximately 36% of overall category share in 2026. This leadership stems from ESAs' long-established clinical use, extensive physician familiarity, and proven efficacy in stimulating red blood cell production among dialysis patients. Leading manufacturers, including Amgen Inc. and F. Hoffmann-La Roche Ltd., continue to maintain strong ESA product portfolios supported by decades of clinical data. Despite growing competition from newer treatment classes, ESAs remain deeply embedded in standard anemia management protocols across dialysis centers worldwide. HIF-PH inhibitors represent the fastest-growing segment, driven by rising clinical adoption of oral therapies offering improved convenience and comparable efficacy to injectable alternatives.

Route of Administration Insights

Intravenous administration leads the route of administration category, supported by its widespread use during dialysis sessions, allowing seamless integration of anemia treatment into existing patient care workflows. This route benefits from established clinical infrastructure within dialysis centers, where intravenous access is already utilized for the dialysis procedure itself. Companies such as Sanofi S.A. and GlaxoSmithKline plc maintain strong positions in intravenous iron therapy formulations. Oral administration represents the fastest-growing route segment, driven by rising adoption of HIF-PH inhibitor therapies that offer patients greater treatment flexibility and reduced dependence on clinical administration settings.

End-user Insights

Dialysis centers constitute the leading end-user segment, reflecting the concentration of anemia treatment administration within specialized outpatient dialysis facilities where patients receive regular hemodialysis sessions. This segment benefits from established clinical protocols integrating anemia management directly into routine dialysis care, with companies such as Astellas Pharma Inc. maintaining strong distribution relationships with dialysis center networks. Home care represents the fastest-growing end-user segment, driven by rising adoption of home-based dialysis modalities and growing availability of self-administered anemia treatment formulations suited to decentralized care settings.

North America Dialysis Induced Anemia Treatment Market Trends and Insights

North America leads the global dialysis induced anemia treatment market, supported by a large and growing dialysis patient population, well-established reimbursement infrastructure, and strong presence of leading pharmaceutical manufacturers. Continued clinical adoption of novel HIF-PH inhibitor therapies reinforces the region's dominant position within the global anemia treatment landscape.

U.S. Dialysis Induced Anemia Treatment Market Size

The United States accounts for the majority of North America's dialysis induced anemia treatment demand, supported by comprehensive Medicare coverage for end-stage renal disease care and strong dialysis center network density. Growing adoption of oral HIF-PH inhibitor therapies continues to drive steady market expansion across the country.

Europe Dialysis Induced Anemia Treatment Market Trends and Insights

Europe represents a mature dialysis induced anemia treatment market, supported by strong regulatory harmonization under the European Medicines Agency (EMA) and well-established national dialysis care infrastructure. Growing biosimilar ESA adoption continues to shape competitive dynamics and cost management strategies across the region.

Germany Dialysis Induced Anemia Treatment Market Size

Germany holds a leading position within Europe's dialysis induced anemia treatment market, supported by strong domestic dialysis center infrastructure and high per-capita chronic kidney disease treatment rates. Growing adoption of advanced iron therapy formulations continues to reinforce the country's strong market performance.

U.K. Dialysis Induced Anemia Treatment Market Size

The United Kingdom maintains a significant share within Europe, supported by National Health Service (NHS) coverage for dialysis care and structured anemia management protocols. Continued clinical guideline updates from the National Institute for Health and Care Excellence (NICE) sustain steady treatment adoption across the country.

France Dialysis Induced Anemia Treatment Market Size

France contributes meaningfully to the European market, supported by comprehensive public healthcare coverage for dialysis and anemia management therapies. Rising adoption of novel treatment classes continues to support steady category growth across the French dialysis care landscape.

Asia Pacific Dialysis Induced Anemia Treatment Market Trends and Insights

Asia Pacific is projected to be the fast-growing region in the dialysis induced anemia treatment market, driven by rising chronic kidney disease prevalence, expanding dialysis center infrastructure, and growing healthcare investment. China represents a key regional growth driver, supported by rapid expansion of domestic dialysis care capacity and growing HIF-PH inhibitor adoption.

The global dialysis induced anemia treatment market remains moderately consolidated, with established pharmaceutical companies holding significant share through long-standing ESA and iron therapy portfolios alongside emerging HIF-PH inhibitor developers. Leading players continue to pursue strategic partnerships, regulatory approvals, and geographic expansion to strengthen their competitive positioning. Research and development investment increasingly focuses on novel oral therapies, improved safety profiles, and extended dosing intervals. Key differentiators among market leaders include clinical trial data depth, regulatory approval breadth, and established dialysis center relationships. Emerging business models increasingly emphasize licensing partnerships and regional distribution agreements to expand market reach across emerging economies.

Key Developments:

• In June 2026, Akebia Therapeutics and U.S. Renal Care announced that the independent Data Monitoring Committee recommended early termination of the Phase IV VOICE trial after a planned interim analysis demonstrated statistically significant superiority of Vafseo® (vadadustat) over erythropoiesis-stimulating agents (ESAs) in the primary composite endpoint of all-cause mortality and hospitalization.
• In December 2025, Insilico Medicine entered into an exclusive licensing agreement with TaiGen Biotechnology, granting the company rights to develop, commercialize, and sublicense ISM4808, an AI-designed oral prolyl hydroxylase domain (PHD) inhibitor, across Greater China for the treatment of anemia associated with chronic kidney disease (CKD).